AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02498717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RICE
Description: SOC ice and elevation
Study NCT04188314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: The control group will receive Isoflurane for maintenance of anesthesia. The quality of recovery score will be compared post-operatively with patients in the intervention group who received desflurane.
Study NCT02466230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
Study NCT01565850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Description: DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
Study NCT01565850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRV
Description: DRV 800 mg (2 × 400 mg tablets) administered orally once daily
Study NCT01565850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COBI
Description: COBI 150 mg tablet administered orally once daily
Study NCT01565850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
Study NCT01565850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D/C/F/TAF Placebo
Description: D/C/F/TAF placebo tablet administered orally once daily
Study NCT01565850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV Placebo
Description: DRV placebo tablet administered orally once daily
Study NCT01565850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI Placebo
Description: COBI placebo tablet administered orally once daily
Study NCT01565850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF Placebo
Description: FTC/TDF placebo tablet administered orally once daily
Study NCT03425734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
Study NCT02882672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
Study NCT02882672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: They did not do ant exercise training during 8 weeks.
Study NCT04178161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
Study NCT01870882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional retraining
Study NCT01870882 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control condition
Study NCT03744871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: N95 Respirator
Description: SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
Study NCT02244879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: resveratrol
Description: arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
Study NCT02244879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
Study NCT03274882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S95005
Description: The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
Study NCT03021252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity IEMT
Description: Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
Study NCT03021252 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham IEMT
Description: 5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
Study NCT03483207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
Study NCT00848419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural administration of bolus
Study NCT00848419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural administration of bolus
Study NCT02831660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarucizumab
Study NCT03767439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 150 mg PO daily
Study NCT03767439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg IV every 4 weeks
Study NCT03767439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg IV every 6 weeks
Study NCT01787383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel 0.05 %
Description: Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
Study NCT02195297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream
Description: Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
Study NCT01787383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel 0.015 %
Description: Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
Study NCT03901638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tllsh2910
Description: Tllsh2910 80mg twice per day orally for 12 weeks
Study NCT03901638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02669498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine fallopian tube removal
Description: Fallopian tubes are removed by dissection of the Mesosalpinx.
Study NCT04686344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermittent boluses of Hypertonic saline
Description: intermittent boluses every 6 hours over 30 min for 48 hours
Study NCT04686344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of Hypertonic saline
Description: continuous infusion over a period of 48 hours
Study NCT03553537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 10mg/m² iv on day 1-5
Study NCT03553537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m² iv on day 6
Study NCT03553537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m² iv on day 6
Study NCT01157663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted balance training
Description: during 8 weeks
Study NCT01157663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Balance training with unipedal standing during 8 weeks
Study NCT01066026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid with metallic cannula or standard needle.
Description: The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~* In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~* In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula.
Study NCT01066026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid with metallic cannula or standard needle.
Description: The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~* In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~* In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula.
Study NCT01066026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injected with the new tool.
Description: hyaluronic acid with metallic cannula.
Study NCT00890305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011
Study NCT00890305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours).
Study NCT00890305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours).
Study NCT00094822 — intervention group
Intervention type: OTHER
Intervention: PI Discretion
Description: PI Discretion
Study NCT04286113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
Study NCT04286113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle management
Description: Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
Study NCT00609336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00609336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00609336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT00609336 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT00609336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00609336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreatic surgical procedure
Description: Undergo pancreaticoduodenectomy
Study NCT00609336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo therapeutic conventional surgery
Study NCT00609336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03206515 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 18F Peel-Way Sheath
Description: Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
Study NCT03206515 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 18F access sheath with a suction-evacuation function
Description: Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
Study NCT03991286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin 8 mg
Description: experimental
Study NCT03991286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo pill
Study NCT03553537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: DOX
Study NCT03553537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: DOX
Study NCT01216761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: 2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
Study NCT01216761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone iodine
Description: 10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
Study NCT02130154 — intervention group
Intervention type: OTHER
Intervention: 18-FDG PET CT scan and 123I-MIBG SPECT scan
Study NCT01241019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia
Description: TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
Study NCT01450956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
Study NCT01450956 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Patients will receive only oxygen and air through oxygenator
Study NCT03937258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions
Study NCT03937258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Probenecid
Description: In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
Study NCT04176744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uni- and bilateral magnetic phrenic nerve stimulation
Description: Uni- and bilateral magnetic phrenic nerve stimulation using different coils, stimulation patterns (frequency, intensity, number of pulses) and locations (neck, chest).
Study NCT01287481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Emotions
Description: Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
Study NCT01287481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thoughts and Behaviors
Description: Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
Study NCT03483207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MVT with failure of anticoagulation therapy
Description: patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded.
Study NCT03483207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
Study NCT00891839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine at 90 mg/m\^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
Study NCT00891839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients receive 375 mg/m\^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
Study NCT04048343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Experimental: Tezepelumab
Description: Tezepelumab subcutaneous injection every 4 weeks
Study NCT03052413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrafol
Description: Eligible subjects will receive Nutrafol® to take daily for 180 days
Study NCT03052413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Eligible subjects will receive Placebo to take daily for 180 days
Study NCT03553537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m² iv on day 6
Study NCT03553537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m² iv on day 6
Study NCT02668250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OPTI-AGED
Description: OPTI-AGED is composed of a multi-parametric optimization strategy.
Study NCT02668250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients receive the usual care.
Study NCT02395913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surfolase capsule (100mg)
Description: Surfolase capsule one capsule twice one days fasting administration
Study NCT02395913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR (200mg, T1)
Description: one tablet once one days fasting administration.
Study NCT02395913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR (200mg, T3)
Description: one tablet once one days fasting administration.